NSCLC (Non-small Cell Lung Carcinoma)Phase 2NCT07842471
Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
A Phase 2 study testing Immediate Local Consolidative Therapy (LCT) in people with NSCLC (Non-small Cell Lung Carcinoma), run by Guangdong Provincial People's Hospital at 1 site in China.
Trial summary
This study explores the difference in progression-free survival (PFS) between local consolidative therapy (LCT arm) targeting residual lesions and continued systemic therapy (non-LCT arm) in patients with metastatic NSCLC who have achieved at least partial response (PR) following first-line chemoimmunotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- NSCLC (Non-small Cell Lung Carcinoma)
- What is being tested?
- Immediate Local Consolidative Therapy (LCT)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 117 participants
- Where
- 1 siteChina
- Study dates
- 8 Oct 2026to 31 Dec 2032
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntary participation in the study with signed informed consent;
- Age ≥18 years, both male and female;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- Estimated life expectancy ≥12 months;
- Histologically/cytologically confirmed non-small cell lung cancer (NSCLC) at initial diagnosis, with TNM stage IV (IASLC 9th edition);
- Absence of actionable genetic mutations related to EGFR/ALK/ROS1 and other druggable targets;
Show all 10Show fewer
- Completion of 4-6 cycles of immunotherapy (PD-1/PD-L1 monoclonal antibody) combined with platinum-based doublet chemotherapy prior to enrollment;
- Achievement of partial response (PR) or complete response (CR) as assessed by RECIST 1.1 criteria;
- Presence of metabolically active residual lesions on PET evaluation, and clinical assessment by the multidisciplinary team (MDT)* indicating feasibility of individualized local therapy (e.g., ≤3 organs and ≤5 lesions, amenable to surgery/radiotherapy/ablation);
- Adequate organ function.
Who cannot join
- Expected to be unable to tolerate surgery, radiation therapy, or ablation;
- Unable to receive local treatment for all active residual lesions;
- Patients with a confirmed history of malignant pleural effusion or pleural dissemination;
- Pathologically diagnosed with neuroendocrine cancer at initial diagnosis (including small cell lung cancer, combined small cell lung cancer, large cell neuroendocrine carcinoma, mixed large cell neuroendocrine carcinoma, and carcinoid). Patients who do not show neuroendocrine components at initial diagnosis but develop such components in post-surgical pathology may be included;
- Previously received allogeneic tissue or solid organ transplantation;
- History of interstitial lung disease requiring steroid treatment (non-infectious) or currently suffering from interstitial lung disease requiring steroid treatment;
Show all 16Show fewer
- Presence of viral infectious diseases during screening:
- Positive serum test for human immunodeficiency virus (HIV);
- Active hepatitis B: positive hepatitis B surface antigen (HBsAg) and HBV-DNA quantitative test >500 IU/mL or >2000 copies/mL;
- Active hepatitis C: positive hepatitis C virus (HCV) antibody and HCV-RNA quantitative test above the upper limit of normal;
- Participants with uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg (adjustment of antihypertensive medications is allowed prior to study initiation, but the average of the most recent three consecutive blood pressure readings before enrollment must be ≤150/90 mmHg) (each measurement separated by at least 2 minutes);
- Active infection requiring intravenous antimicrobial therapy at screening;
- Diagnosis of another malignancy within 3 years prior to signing informed consent, excluding cured cases of cutaneous basal cell carcinoma, cervical or breast in situ carcinoma, superficial bladder cancer, localized prostate cancer; participants with low-risk early-stage prostate cancer (T1-T2a stage, Gleason score ≤6, PSA <10 ng/mL) are eligible if they have undergone curative treatment or are under active surveillance with stable disease, regardless of whether they have received treatment;
- Conditions that may interfere with interpretation of study results or affect the participant's ability to complete the entire study, or where, in the investigator's judgment, participation does not serve the participant's best interest;
- Pregnant, breastfeeding, or planning pregnancy; positive pregnancy test within 7 days prior to first study treatment;
- Poor compliance, unwillingness or inability to follow the study procedures as required.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Guangdong Provincial People's Hospital
Guangzhou, Guangzhou, 510080
Wen-Zhao Zhong, MD,PhD, +86-020-83827812, ruifu66@foxmail.com
About this study
Official title: A Phase II, Multicenter, Randomized, Patient-Centered Study of the Efficacy and Safety of Immediate Local Consolidative Therapy (LCT) Versus Continued Immunotherapy Maintenance or Delayed Local Therapy (Non-LCT) After First-Line Chemoimmunotherapy in Metastatic NSCLC, Assessed by MDT
This study explores the difference in progression-free survival (PFS) between local consolidative therapy (LCT arm) targeting residual lesions and continued systemic therapy (non-LCT arm) in patients with metastatic NSCLC who have achieved at least partial response (PR) following first-line chemoimmunotherapy. In this process, a multidisciplinary team (MDT) comprising surgical oncology, radiation oncology, and medical oncology will be integrated to administer local treatment modalities-including surgery, radiotherapy, and ablation-for oligometastatic lesions, aiming to address critical clinical questions regarding the optimal beneficiary population for local therapy, the best local treatment modality, and the optimal timing of local intervention.
Read the detailed description
- This study incorporates both a randomized controlled trial (RCT) cohort and a real-world study (RWS) cohort. RCT Cohort: A prospective, randomized, multicenter clinical study. The primary study population comprises patients with stage IV disease (9th edition TNM staging) who have received 4-6 cycles of first-line immunotherapy combined with platinum-based doublet chemotherapy, achieved at least partial response (PR) upon efficacy assessment, demonstrated metabolically active residual lesions on PET evaluation, and been clinically assessed by the multidisciplinary team (MDT) as amenable to individualized local therapy (e.g., ≤3 organs and ≤5 lesions, with feasibility for surgery/radiotherapy/ablation). Patients will be randomly assigned to: Local Therapy Arm: Receiving local treatment targeting residual lesions, followed by physician-assessed continuation of maintenance systemic therapy or surveillance monitoring; optional local treatment modalities include surgery, radiotherapy, and ablation. Assessment of residual lesions will be primarily based on imaging examinations including PET-CT and brain MRI. PET evaluation of residual lesions will primarily reference the PERCIST (PET Response Criteria in Solid Tumors) criteria. Compared with baseline imaging, lesions with metabolic activity exceeding that of the mediastinal blood pool or liver on PET evaluation will be considered potentially active residual lesions. The final determination shall be made through multidisciplinary assessment jointly by a radiologist or nuclear medicine physician with more than 10 years of clinical experience, together with thoracic surgeons, pulmonologists, and radiation oncologists. Systemic Therapy Arm: Continuation of systemic maintenance therapy until disease progression (PD) or intolerable toxicity; upon PD, patients may undergo MDT reassessment for potential local therapy opportunities.
- Primary Endpoint: Progression-Free Survival (PFS): Time from randomization to first documented disease progression or death from any cause.
- Secondary Endpoints: Overall Survival (OS): Time from randomization to death from any cause. Safety of local consolidative therapy. Impact of different local consolidative treatment modalities on prognosis. Time from local consolidative therapy to recurrence/progression of previously existing metastatic lesions. Time from local consolidative therapy to development of new metastatic lesions.
- Exploratory Endpoints: Tumor Immune Microenvironment (TiME) and prognosis. Tumor dormancy characteristics. Clinical outcomes of different treatment choices after disease progression (PD) in the control arm. Correlation between ctDNA-based minimal residual disease (MRD) status before and after randomization and prognosis.
- RCT Cohort: The time from randomization to disease progression (PD) or death in the control arm following induction therapy was 6 months. Assuming that the experimental arm combined with local therapy could be extended to 11 months (based on clinical experience and literature inference), with a one-sided α of 0.05, power of 80%, accrual period of 12 months, and a randomization ratio of 2:1, the total required sample size was calculated to be 105 patients (with a total of 76 required events), comprising 70 patients in the experimental arm and 35 patients in the control arm. Considering an 8%-10% dropout rate, a total of 117 patients are planned for enrollment.
- RWS Cohort: This cohort does not prespecify statistical hypotheses. It is designed to observe patients who met the eligibility criteria during the RCT study period but were unable to be enrolled in the RCT for various reasons. This cohort will serve to supplement the safety and clinical benefit data of the experimental arm in the RCT cohort. Based on epidemiological projections from our center, approximately 50 patients are expected to be enrolled during this period.
- Conditions
- NSCLC (Non-small Cell Lung Carcinoma)
- Being tested
- Immediate Local Consolidative Therapy (LCT)
- Keywords
- local consolidative therapy, surgery, radiotherapy, ablation, immunotherapy
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Immediate Local Consolidative Therapy (LCT)Procedure or surgery
Also called radiotherapy, ablation
Patients with stage IV disease (9th edition TNM staging) who have received 4-6 cycles of first-line immunotherapy combined with platinum-based doublet chemotherapy, achieved at least partial response (PR) upon efficacy assessment, demonstrated metabolically active residual lesions on PET evaluation, and been clinically assessed by the multidisciplinary team (MDT) as amenable to individualized local therapy. And then receiving local treatment targeting residual lesions, followed by physician-assessed continuation of maintenance systemic therapy or surveillance monitoring; optional local treatment modalities include surgery, radiotherapy, and ablation.
| Study group | Role | What they receive |
|---|---|---|
| LCT | Experimental | Receiving local treatment targeting residual lesions, followed by physician-assessed continuation of maintenance systemic therapy or surveillance monitoring; optional local treatment modalities include surgery, radiotherapy, and ablation. Assessment of residual lesions will be primarily based on imaging examinations including PET-CT and brain MRI. PET evaluation of residual lesions will primarily reference the PERCIST (PET Response Criteria in Solid Tumors) criteria. Compared with baseline imaging, lesions with metabolic activity exceeding that of the mediastinal blood pool or liver on PET evaluation will be considered potentially active residual lesions. The final determination shall be made through multidisciplinary assessment jointly by a radiologist or nuclear medicine physician with more than 10 years of clinical experience, together with thoracic surgeons, pulmonologists, and radiation oncologists. Receives: Procedure: Immediate Local Consolidative Therapy (LCT) |
| non-LCT | No intervention | Continuation of systemic maintenance therapy until disease progression (PD) or intolerable toxicity; upon PD, patients may undergo MDT reassessment for potential local therapy opportunities. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival (PFS)
Measured: Time from randomization to the date of the first documentation of disease progression according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death from any cause, whichever is earlier, assessed up to 60 months.
Secondary outcomes (5)
Overall Survival (OS)
Measured: time from randomization to the date of death from any cause, assessed up to 60 months.
Safety of local consolidative therapy.
Safety follow-up will be conducted at 30 days (±5 days) after local therapy or prior to the first maintenance therapy following local therapy. Occurrence and severity of adverse events, with severity determined by NCI CTCAE v6.0 criteria.
Measured: 30 days (±5 days) after local therapy or prior to the first maintenance therapy following local therapy.
Impact of different local consolidative treatment modalities on prognosis.
Impact of different local consolidative treatment modalities on PFS and OS.
Measured: When a PFS or OS event occurs
Time from local consolidative therapy to recurrence/progression of previously existing metastatic lesions.
Measured: From date of local consolidative therapy until the date of first documented recurrence/progression of previously existing metastatic lesions, assessed up to 60 months..
Time from local consolidative therapy to development of new metastatic lesions.
Measured: From date of local consolidative therapy until the date of first documented new distant metastasis, assessed up to 60 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start8 Oct 2026 (estimated)
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NSCLC (Non-small Cell Lung Carcinoma)Studies of the same condition, open and under way.
- More trials run by Guangdong Provincial People's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 117 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guangdong Provincial People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wen-zhao ZHONG, Guangdong Provincial People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07842471
- Sponsor's protocol ID
- CTONG 2601
- Status last verified
- Jul 2026
- First submitted
- 5 Aug 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II, Multicenter, Randomized, Patient-Centered Study of the Efficacy and Safety of Immediate Local Consolidative Therapy (LCT) Versus Continued Immunotherapy Maintenance or Delayed Local Therapy (Non-LCT) After First-Line Chemoimmunotherapy in Metastatic NSCLC, Assessed by MDT
- ClinicalTrials.gov ID
- NCT07842471
- Acronym / sponsor ID
- CTONG 2601
- Conditions
- NSCLC (Non-small Cell Lung Carcinoma)
- Keywords
- local consolidative therapy, surgery, radiotherapy, ablation, immunotherapy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 117 participants (estimated)
- Lead sponsor
- Guangdong Provincial People's HospitalUniversity, hospital or other
- Study start
- 8 Oct 2026 (estimated)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study explores the difference in progression-free survival (PFS) between local consolidative therapy (LCT arm) targeting residual lesions and continued systemic therapy (non-LCT arm) in patients with metastatic NSCLC who have achieved at least partial response (PR) following first-line chemoimmunotherapy. In this process, a multidisciplinary team (MDT) comprising surgical oncology, radiation oncology, and medical oncology will be integrated to administer local treatment modalities-including surgery, radiotherapy, and ablation-for oligometastatic lesions, aiming to address critical clinical questions regarding the optimal beneficiary population for local therapy, the best local treatment modality, and the optimal timing of local intervention.
Detailed description
- This study incorporates both a randomized controlled trial (RCT) cohort and a real-world study (RWS) cohort. RCT Cohort: A prospective, randomized, multicenter clinical study. The primary study population comprises patients with stage IV disease (9th edition TNM staging) who have received 4-6 cycles of first-line immunotherapy combined with platinum-based doublet chemotherapy, achieved at least partial response (PR) upon efficacy assessment, demonstrated metabolically active residual lesions on PET evaluation, and been clinically assessed by the multidisciplinary team (MDT) as amenable to individualized local therapy (e.g., ≤3 organs and ≤5 lesions, with feasibility for surgery/radiotherapy/ablation). Patients will be randomly assigned to: Local Therapy Arm: Receiving local treatment targeting residual lesions, followed by physician-assessed continuation of maintenance systemic therapy or surveillance monitoring; optional local treatment modalities include surgery, radiotherapy, and ablation. Assessment of residual lesions will be primarily based on imaging examinations including PET-CT and brain MRI. PET evaluation of residual lesions will primarily reference the PERCIST (PET Response Criteria in Solid Tumors) criteria. Compared with baseline imaging, lesions with metabolic activity exceeding that of the mediastinal blood pool or liver on PET evaluation will be considered potentially active residual lesions. The final determination shall be made through multidisciplinary assessment jointly by a radiologist or nuclear medicine physician with more than 10 years of clinical experience, together with thoracic surgeons, pulmonologists, and radiation oncologists. Systemic Therapy Arm: Continuation of systemic maintenance therapy until disease progression (PD) or intolerable toxicity; upon PD, patients may undergo MDT reassessment for potential local therapy opportunities.
- Primary Endpoint: Progression-Free Survival (PFS): Time from randomization to first documented disease progression or death from any cause.
- Secondary Endpoints: Overall Survival (OS): Time from randomization to death from any cause. Safety of local consolidative therapy. Impact of different local consolidative treatment modalities on prognosis. Time from local consolidative therapy to recurrence/progression of previously existing metastatic lesions. Time from local consolidative therapy to development of new metastatic lesions.
- Exploratory Endpoints: Tumor Immune Microenvironment (TiME) and prognosis. Tumor dormancy characteristics. Clinical outcomes of different treatment choices after disease progression (PD) in the control arm. Correlation between ctDNA-based minimal residual disease (MRD) status before and after randomization and prognosis.
- RCT Cohort: The time from randomization to disease progression (PD) or death in the control arm following induction therapy was 6 months. Assuming that the experimental arm combined with local therapy could be extended to 11 months (based on clinical experience and literature inference), with a one-sided α of 0.05, power of 80%, accrual period of 12 months, and a randomization ratio of 2:1, the total required sample size was calculated to be 105 patients (with a total of 76 required events), comprising 70 patients in the experimental arm and 35 patients in the control arm. Considering an 8%-10% dropout rate, a total of 117 patients are planned for enrollment.
- RWS Cohort: This cohort does not prespecify statistical hypotheses. It is designed to observe patients who met the eligibility criteria during the RCT study period but were unable to be enrolled in the RCT for various reasons. This cohort will serve to supplement the safety and clinical benefit data of the experimental arm in the RCT cohort. Based on epidemiological projections from our center, approximately 50 patients are expected to be enrolled during this period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LCT | Experimental | Procedure: Immediate Local Consolidative Therapy (LCT)Receiving local treatment targeting residual lesions, followed by physician-assessed continuation of maintenance systemic therapy or surveillance monitoring; optional local treatment modalities include surgery, radiotherapy, and ablation. Assessment of residual lesions will be primarily based on imaging examinations including PET-CT and brain MRI. PET evaluation of residual lesions will primarily reference the PERCIST (PET Response Criteria in Solid Tumors) criteria. Compared with baseline imaging, lesions with metabolic activity exceeding that of the mediastinal blood pool or liver on PET evaluation will be considered potentially active residual lesions. The final determination shall be made through multidisciplinary assessment jointly by a radiologist or nuclear medicine physician with more than 10 years of clinical experience, together with thoracic surgeons, pulmonologists, and radiation oncologists. |
| non-LCT | No intervention | –Continuation of systemic maintenance therapy until disease progression (PD) or intolerable toxicity; upon PD, patients may undergo MDT reassessment for potential local therapy opportunities. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Voluntary participation in the study with signed informed consent;
- Age ≥18 years, both male and female;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- Estimated life expectancy ≥12 months;
- Histologically/cytologically confirmed non-small cell lung cancer (NSCLC) at initial diagnosis, with TNM stage IV (IASLC 9th edition);
Key exclusion criteria (16 listed)
- Expected to be unable to tolerate surgery, radiation therapy, or ablation;
- Unable to receive local treatment for all active residual lesions;
- Patients with a confirmed history of malignant pleural effusion or pleural dissemination;
- Pathologically diagnosed with neuroendocrine cancer at initial diagnosis (including small cell lung cancer, combined small cell lung cancer, large cell neuroendocrine carcinoma, mixed large cell neuroendocrine carcinoma, and carcinoid). Patients who do not show neuroendocrine components at initial diagnosis but develop such components in post-surgical pathology may be included;
- Previously received allogeneic tissue or solid organ transplantation;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Immediate Local Consolidative Therapy (LCT)Also: radiotherapy, ablationPatients with stage IV disease (9th edition TNM staging) who have received 4-6 cycles of first-line immunotherapy combined with platinum-based doublet chemotherapy, achieved at least partial response (PR) upon efficacy assessment, demonstrated metabolically active residual lesions on PET evaluation, and been clinically assessed by the multidisciplinary team (MDT) as amenable to individualized local therapy. And then receiving local treatment targeting residual lesions, followed by physician-assessed continuation of maintenance systemic therapy or surveillance monitoring; optional local treatment modalities include surgery, radiotherapy, and ablation. | Procedure or surgery | LCT |
Primary outcome
Progression-Free Survival (PFS)
Time frame: Time from randomization to the date of the first documentation of disease progression according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death from any cause, whichever is earlier, assessed up to 60 months.
5 secondary outcomes
Overall Survival (OS)
Time frame: time from randomization to the date of death from any cause, assessed up to 60 months.
Safety of local consolidative therapy.
Time frame: 30 days (±5 days) after local therapy or prior to the first maintenance therapy following local therapy.
Impact of different local consolidative treatment modalities on prognosis.
Time frame: When a PFS or OS event occurs
Time from local consolidative therapy to recurrence/progression of previously existing metastatic lesions.
Time frame: From date of local consolidative therapy until the date of first documented recurrence/progression of previously existing metastatic lesions, assessed up to 60 months..
Time from local consolidative therapy to development of new metastatic lesions.
Time frame: From date of local consolidative therapy until the date of first documented new distant metastasis, assessed up to 60 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for NSCLC (Non-small Cell Lung Carcinoma)
RecruitingPhase 3
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
IO Resistant Squamous and Nonsquamous NSCLC
RecruitingPhase 3
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Non-small Cell Lung Cancer
Not yet recruitingPhase 1
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
RecruitingPhase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Immediate Local Consolidative Therapy (LCT) in people with NSCLC (Non-small Cell Lung Carcinoma), run by Guangdong Provincial People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wen-Zhao Zhong, MD, PhD (+86-020-83827812, syzhongwenzhao@scut.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival (PFS) (time frame: Time from randomization to the date of the first documentation of disease progression according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death from any cause, whichever is earlier, assessed up to 60 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.